Pal, S. K., Sweiss, R. F., Kotecha, R., Runcie, K., Bilen, M., Msaouel, P., … Garmezy, B. (2025). Abstract B006: Preliminary Phase 1 safety and antitumor activity of XmAb819, a first-in-class ENPP3 x CD3 bispecific antibody, in patients with advanced clear cell renal cell carcinoma (ccRCC). In Molecular Cancer Therapeutics (Vol. 24, pp. B006–B006). American Association for Cancer Research (AACR). https://doi.org/10.1158/1535-7163.targ-25-b006

Pal, Sumanta Kumar, Randy F. Sweiss, Ritesh Kotecha, Karie Runcie, Mehmet Bilen, Pavlos Msaouel, David A. Braun, et al. “Abstract B006: Preliminary Phase 1 safety and antitumor activity of XmAb819, a first-in-class ENPP3 x CD3 bispecific antibody, in patients with advanced clear cell renal cell carcinoma (ccRCC).” In Molecular Cancer Therapeutics, 24:B006–B006. American Association for Cancer Research (AACR), 2025. https://doi.org/10.1158/1535-7163.targ-25-b006.

Pal SK, Sweiss RF, Kotecha R, Runcie K, Bilen M, Msaouel P, et al. Abstract B006: Preliminary Phase 1 safety and antitumor activity of XmAb819, a first-in-class ENPP3 x CD3 bispecific antibody, in patients with advanced clear cell renal cell carcinoma (ccRCC). In: Molecular Cancer Therapeutics. American Association for Cancer Research (AACR); 2025. p. B006–B006.

Pal, Sumanta Kumar, et al. “Abstract B006: Preliminary Phase 1 safety and antitumor activity of XmAb819, a first-in-class ENPP3 x CD3 bispecific antibody, in patients with advanced clear cell renal cell carcinoma (ccRCC).” Molecular Cancer Therapeutics, vol. 24, no. 10_Supplement, American Association for Cancer Research (AACR), 2025, pp. B006–B006. Crossref, doi:10.1158/1535-7163.targ-25-b006.

Pal SK, Sweiss RF, Kotecha R, Runcie K, Bilen M, Msaouel P, Braun DA, Tykodi SS, Hoimes C, Bohac C, Suri V, Kanodia J, Salama E, Woo J, Berhe S, Yang Y, Franklin R, Grigg C, Maly J, Gulati S, Vanderweele DJ, Ayanambakkam A, Saraiya B, Garmezy B. Abstract B006: Preliminary Phase 1 safety and antitumor activity of XmAb819, a first-in-class ENPP3 x CD3 bispecific antibody, in patients with advanced clear cell renal cell carcinoma (ccRCC). Molecular Cancer Therapeutics. American Association for Cancer Research (AACR); 2025. p. B006–B006.